title: [Acquired von Willebrand disease and lymphoproliferative syndromes].
abstract: OBJECTIVE
  Acquired von Willebrand disease occurs in patients with or without cutaneous and mucosal bleeding who have no personal or family history of the disease. The clinical course of these patients is poorly known due to the rarity of acquired von Willebrand factor (vWF) deficit. We conducted this study to assess the clinical course of acquired vWF deficit secondary to lymphoproliferative syndromes.
  
  
  METHODS
  We report the clinical course of acquired von Willebrand disease in 6 patients with monoclonal gammapathy of undetermined significance, multiple myeloma, chronic lymphoid leukemia, Wadenstöm's macroglobulinemia, or lymphoma who were followed for 1 to 11 years.
  
  
  RESULTS
  Acquired von Willebrand disease was suspected in non-thrombocytopenic patients with a lymphoproliferative syndrome who developed a hemorrhagic syndrome. The vWF anomaly was symptomatic in 4 of 6 patients at diagnosis. Patients were given symptomatic treatment with vWF replacement therapy as needed and specific treatment for their lymphoproliferative syndrome. Administration of DDAVP was sufficient in 3 out of 4 patients to allow invasive procedures but was unable to control digestive ulcer bleeding that required infusion of factor VIII-vWF concentrate. For 2 patients, chemotherapy was initiated due to threatening massive hemorrhage. The result was spectacular. The 4 other patients have been asymptomatic without treatment for 3, 5, 6 and 11 years during which time their lymphoproliferative syndrome has been quiescent.
  
  
  CONCLUSIONS
  The clinical features and laboratory findings are similar in patients with congenital or acquired von Willebrand disease, but specific and etiologic chemotherapy is indicated for patients with acquired disease.
authors.affiliation: Service des Maladies du Sang, CHU, 4, rue Larrey, F49033 Angers.
authors.forename: M
authors.initials: M
authors.lastname: Hunault-Berger
authors.forename: P
authors.initials: P
authors.lastname: Rachieru
authors.forename: C
authors.initials: C
authors.lastname: Ternisien
authors.forename: H
authors.initials: H
authors.lastname: Jardel
authors.forename: M
authors.initials: M
authors.lastname: Zandecki
authors.forename: M
authors.initials: M
authors.lastname: Boasson
authors.forename: N
authors.initials: N
authors.lastname: Ifrah
mesh_terms: D000368:Aged; D005260:Female; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000150:complications*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D014842:von Willebrand Diseases / Q000209:etiology* / Q000473:pathology; D014841:von Willebrand Factor / Q000627:therapeutic use
chemical_list: D014841:von Willebrand Factor